Roche CEO Sev­erin Schwan isn’t about to tam­per with a win­ning R&D strat­e­gy now, but he’s still look­ing for ways to cut costs

For years now Roche has dom­i­nat­ed the very top cir­cle of Big Phar­ma R&D, in­vest­ing more than $8 bil­lion a year in drug de­vel­op­ment through a glob­al net­work of re­search cen­ters con­cen­trat­ed at Chugai, gRED in South San Fran­cis­co and pRED out of Basel. And as far as CEO Sev­erin Schwan is con­cerned, that’s a win­ning for­mu­la that he has no plans to tam­per with, even as Roche digs in­to its vast R&D ops in search of some greater ef­fi­cien­cies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER